Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07083076 · ClinicalTrials.gov registry record · NA
Regular Diet Versus Extended Low Residue After Colon Surgery
A NA study of Colon Resection, sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 222
- Enrollment target
- 2
- Study locations
NCT07083076: Recruiting NA study of Colon Resection, sponsored by Northwell Health.
NCT07083076 is a NA study of Colon Resection that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 222 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07083076, a NA study of Colon Resection, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 222 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if a 10 day low-residue diet restriction is better for bowel function and quality of life without increasing complications compared to a 6 week low-residue diet restriction after elective colon resection surgery. The main questions it aims to answer are: Does a shorter time period of low residue restriction result in a faster return to normal bowel function? Are there any differences in complication rate between a 10 day low-residue diet restriction compared to a 6 week low-residue diet restriction? Participants will be randomized to one of the two diet plans and will be asked to answer surveys about their bowel function and health care related quality of life at various time points for up to 3 months.
Primary Outcome
Return to baseline bowel function is defined by comparing the preoperative LARS score (range 0-42) to postoperative LARS score (range 0-42). Return to baseline is defined as a difference equal to or less than 5 when subtracting the postoperative score by the preoperative score.
Conditions Studied
Interventions
- OTHER Short term (10 day) low residue diet restriction
- OTHER 6 week low residue diet restriction
Study Locations (2)
New York
- North Shore University Hospital - Manhasset
- Long Island Jewish Hospital - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2028-07-01 |
| Phase | NA |
What NCT07083076 shows while recruiting
NCT07083076 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Colon Resection appearing as the primary indexed condition, and to 2 interventions - of which Short term (10 day) low residue diet restriction is the first listed.
NCT07083076 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07083076 about?
NCT07083076 is a clinical study titled "Regular Diet Versus Extended Low Residue After Colon Surgery". The goal of this clinical trial is to learn if a 10 day low-residue diet restriction is better for bowel function and quality of life without increasing complications compared to a 6 week low-residue diet restriction after elective colon resection surgery. The main questions it aims to answer are: ...
What is the current status of trial NCT07083076?
This trial is currently recruiting. It is a NA study. The enrollment target is 222 participants. The study started on 2025-09-19. Estimated completion is 2028-07-01.
What conditions does trial NCT07083076 study?
This clinical trial studies the following conditions: Colon Resection.
What interventions are being tested in trial NCT07083076?
The interventions under investigation include: Short term (10 day) low residue diet restriction (OTHER), 6 week low residue diet restriction (OTHER).
Who is sponsoring clinical trial NCT07083076?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07083076 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07083076's enrollment target sits among peer trials
222 481st of 2000 higher than 1,520 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI